Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Angela Stupi

Rheumatology Cranberry Twp, PA Medical Doctor

NPI 1619975984 CMS profile 409221

144 Emeryville Dr Ste 220, Cranberry Twp, PA 16066

Open in the dashboard

General payments

$134,730

2,385 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$201,136 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Angela Stupi of Cranberry Twp, PA is reported in the CMS Open Payments database as having received $134,730 across 2,385 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $201,136 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,241 294
2024 General $7,396 303
2023 General $15,834 367
2022 General $11,922 335
2021 General $13,822 346
2020 General $15,632 282
2019 General $57,883 458

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angela Stupi
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Angela Stupi were reported at $12,241. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Angela Stupi Rheumatology median Middle half National median
2019 $57,883 $744 $153–$2,687 $163
2020 $15,632 $462 $98–$2,027 $114
2021 $13,822 $531 $101–$2,153 $132
2022 $11,922 $627 $125–$2,303 $149
2023 $15,834 $741 $145–$2,524 $160
2024 $7,396 $830 $166–$2,660 $164
2025 $12,241 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $61,473 397 payments
  2. Celgene Corporation $17,022 35 payments
  3. AbbVie, Inc. $9,185 268 payments
  4. Regeneron Healthcare Solutions, Inc. $7,625 29 payments
  5. Horizon Therapeutics plc $6,031 112 payments
  6. Janssen Biotech, Inc. $5,002 273 payments
  7. UCB, Inc. $3,118 125 payments
  8. Alexion Pharmaceuticals, Inc. $2,970 36 payments
  9. Pfizer Inc. $2,798 158 payments
  10. Novartis Pharmaceuticals Corporation $2,096 159 payments
  11. Other $17,412 793 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $68,131 39 payments
  2. Food and Beverage $45,645 2,297 payments
  3. Consulting Fee $8,421 4 payments
  4. Travel and Lodging $7,666 32 payments
  5. Honoraria $3,480 1 payment
  6. Grant $1,200 1 payment
  7. Education $186 11 payments
Products named General payments · program years 2019–2025
  1. Otezla Inflammation $26,271 105 payments
  2. Prolia $24,013 88 payments
  3. Otezla Dermatology $17,022 35 payments
  4. KEVZARA $7,625 29 payments
  5. Otezla Inflammation $7,461 5 payments
  6. RINVOQ $4,670 153 payments
  7. TREMFYA $3,687 167 payments
  8. HUMIRA $3,223 48 payments
  9. SIMPONI ARIA $2,621 168 payments
  10. Cimzia $2,563 107 payments
  11. Other $40,068 2,078 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

567

Median for Rheumatology: 1,511

Drug cost

$2,982,330

Median for Rheumatology: $1,139,948

Branded share of claims

72.7%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 48 $906,764
Krystexxa Pegloticase Brand 14 $824,789
Orencia Abatacept/Maltose Brand 55 $302,730
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 32 $259,785
Saphnelo Anifrolumab-Fnia Brand 35 $176,287
Benlysta Belimumab Brand 32 $113,554
Simponi Aria Golimumab Brand 16 $105,554
Actemra Tocilizumab Brand 50 $97,355
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 12 $88,143
Prolia Denosumab Brand 48 $82,642

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$1,568,435

Of which drugs: $1,411,704

Medicare patients

352

Average age 71

Services billed

114,866

278 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Osteoporosis 39%
Depression 31%
Ischemic heart disease 22%
Diabetes 21%
Chronic kidney disease 20%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 11 5,925 $197,430
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 13 43,204 $153,331
Injection, denosumab, 1 mg J0897 Office 45 4,560 $91,814
Injection, methylprednisolone acetate, 1 mg J1010 Office 77 6,425 $662
Injection, methylprednisolone acetate, 40 mg J1030 Office 46 102 $388
Injection, zoledronic acid, 1 mg J3489 Office 12 60 $322
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 14 37 $36

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
$781 — —
TREMFYA
$668 — —
PURIFIED CORTROPHIN GEL
$616 — —
INJECTAFER
$431 — —
RINVOQ
$406 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

2,385 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record